Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 78 of 2811 for:    tumor | Neuroendocrine Tumors

Use of Video Consultation in Follow-up Care for Patients With a Neuroendocrine Tumor: a Feasibility Study (VIDEO-NET)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02147106
Recruitment Status : Completed
First Posted : May 26, 2014
Last Update Posted : May 5, 2017
Sponsor:
Information provided by (Responsible Party):
A.M.E. Walenkamp, University Medical Center Groningen

Brief Summary:

Rationale: Patients with neuroendocrine tumors (NET) have a rare disease. Due to treating patients with a neuroendocrine tumor in 'NET knowledge centers' patients often have to travel long distances for follow-up visits at the outpatient clinic. Patients whose medical condition allows videoconsultation could save time by replacing outpatient clinic visits through videoconsultation for receiving follow-up care. Therefore, in this study we aim to introduce videoconsultation as a alternative for follow-up outpatient clinic visits in NET patients.

Objective: The primary objective is to assess if use of videoconsultation in follow-up care for NET patients is feasible. We hypothesize that videoconsultation is a suitable medium for providing follow-up care in NET patients. Secondary objectives are to explore the amount of time videoconsultation takes in comparison with outpatient clinic visits and the acceptability and satisfaction of physicians and patients with using videoconsultation in follow-up care.

Study design: The present study is a single-centre prospective feasibility study.

Study population: Adult NET patients under surveillance or treatment of the department Medical Oncology at the University Medical Centre Groningen (UMCG) whose medical condition allows videoconsultation will be invited to participate.

Intervention: Patient who give informed consent will participate in the study. Participants will receive follow-up care through videoconsultation instead of conventional visits at the outpatient clinic.

Main study parameters/endpoints: The main endpoint is the feasibility of videoconsultation for follow-up care in NET patients. We hypothesize that videoconsultation is a suitable medium for providing follow-up care.


Condition or disease Intervention/treatment
Neuroendocrine Tumor Other: Videoconsultation

Layout table for study information
Study Type : Observational
Actual Enrollment : 26 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Use of Video Consultation in Follow-up Care for Patients With a NeuroEndocrine Tumor: a Feasibility Study (VIDEO-NET Study)
Study Start Date : May 2014
Actual Primary Completion Date : March 2017
Actual Study Completion Date : March 2017

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Videoconsultation
Performing two videoconsulations with the treating medical oncologist
Other: Videoconsultation



Primary Outcome Measures :
  1. Feasibility [ Time Frame: 1 year ]
    Participation rates, reason for declining participation, number of completed videoconsultations, dropout rate and reason for dropout will be noted in study records to evaluate feasibility of videoconsultation


Secondary Outcome Measures :
  1. Amount of time [ Time Frame: 1 year ]
    The amount of time NET patients are spending with videoconsultation in comparison with conventional outpatient clinic visits.

  2. Acceptability and satisfaction of patients [ Time Frame: 1 year ]
    The acceptability and satisfaction of patients with the use of videoconsultation will be assessed with a questionnaire and open-ended questions.

  3. Acceptability and satisfaction of physicians [ Time Frame: 1 year ]
    The acceptability and satisfaction of physicians with the use of videoconsultation will be assessed with a questionnaire and open-ended questions.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Neuroendocrine tumor patients (grade 1 and 2) whose medical condition allows videoconsultation.
Criteria

Inclusion Criteria:

  • Signed informed consent
  • Age ≥ 18 yrs
  • Grade I or II (low and intermediate grade) NET with any primary tumor type or disease stage
  • Have access to required equipment/technology for performing videoconsultation

Exclusion Criteria:

  • Newly referred NET patients, who are visiting the department of Medical Oncology at the UMCG for the first time
  • Recently diagnosed NET patients, who are in the diagnostic phase of the disease
  • NET patients who frequently require blood tests, consultation or physical examination
  • A hearing or visual impairment, which would make videoconsultation difficult

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02147106


Locations
Layout table for location information
Netherlands
University Medical Center Groningen
Groningen, Netherlands, 9713 GZ
Sponsors and Collaborators
University Medical Center Groningen
Investigators
Layout table for investigator information
Principal Investigator: A.M.E. Walenkamp, MD PhD University Medical Center Groningen

Layout table for additonal information
Responsible Party: A.M.E. Walenkamp, MD PhD, University Medical Center Groningen
ClinicalTrials.gov Identifier: NCT02147106     History of Changes
Other Study ID Numbers: VIDEO-NET-2014
First Posted: May 26, 2014    Key Record Dates
Last Update Posted: May 5, 2017
Last Verified: May 2017
Keywords provided by A.M.E. Walenkamp, University Medical Center Groningen:
Neuroendocrine tumor
Videoconsultation
Feasibility
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Neoplasms
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue